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It is the third time since the early 21st century that a zoonotic coronavirus (SARS-CoV-2) has crossed species to bring about serious public health events. In December 2019, initial cases with exposure to a wet market that developed acute respiratory disease were first reported in Wuhan, China \[[@B1]\]. Due to its alarming scale of spread and severity, the World Health Organization (WHO) declared the current coronavirus disease (COVID-19) a global pandemic \[[@B2]\]. Like the previous outbreaks caused by coronaviruses, such as the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus, COVID-19 tends to cause unfavorable outcomes. By March 14, 2020, a total of 118,319 cases have been confirmed globally, affecting 135 countries worldwide, and a total of 4,292 deaths have been reported throughout the world \[[@B3]\].

Tracing back to 2003, a medical ward outbreak of SARS associated with 4 dialysis patients was reported in Hong Kong \[[@B4]\]. During the last epidemic, a dialysis unit (DU) outbreak of MERS was reported in Saudi Arabia in 2013 \[[@B5]\]. The uremia state, immunocompromised status, comorbidity burden, frequent hospital visit, and the extracorporeal nature of the therapy are potential risk factors making hemodialysis (HD) patients prone to severe infections. Furthermore, dialysis care delivery requires close contact and multi-person attendance; therefore, DU is at high risk during virus outbreaks. So far, it is unclear how many dialysis patients are involved in the COVID-19 pandemic. A recent study from Wuhan showed that the main causes of death among dialysis patients with COVID-19 were cardiovascular/cerebrovascular disease and hyperkalemia, which was mainly due to the reduction of dialysis times since patients were in fear of contracting the virus \[[@B6]\]. In light of the current pandemic, it is important to exert adequate effort for the management of dialysis patients, caregivers, and healthcare personnel (HCP). The aim of this study is to report practical workflow regarding the infection control precautions and dialysis care delivery, description of high-risk/suspected cases of COVID-19, and subsequent response measures with a case series from our HD units.

Materials and Methods {#sec1_2}
=====================

Infection control guidance and practice suggestions have been updated several times by the national workgroups (i.e., new coronavirus pneumonia national prevention and control program) to cope with the changing situation. Given the SARS experience, dialysis patients may present with less typical clinical characteristics \[[@B7]\]; thus, the criteria for a suspected case in dialysis settings need to be adjusted based on the guidance from the WHO \[[@B8]\] and national workgroups \[[@B9]\] with a combination of dialysis expertise, relaxing the definition of a suspected case or a case of high risk when appropriate. At the time of the COVID-19 outbreak, precautions and clinical practice protocols were adopted and applied in our DU in January 2020. The workflow is shown in Figure [1](#F1){ref-type="fig"}. As a part of the hospital infection prevention and control (IPC) protocol, the north wing of the inpatient building was set up for isolation use, isolation wards with an intensive care unit team were preserved for critical care, and doctors and nurses with dialysis expertise have joined the workforce. Elevators and transportation routes for segregation and cohorting were designated upon patients\' arrival.

COVID-19 testing is mandatory for all patients who will require vascular access procedures. Interdisciplinary consultation and coordination were planned for non-dialysis-dependent patients who developed fever and respiratory illness while being in need of urgent start of dialysis. Rapid turnaround testing and screening for these patients were prioritized. The detailed flowchart is illustrated in Figure [2](#F2){ref-type="fig"}.

For screening purpose, laboratory testing for complete blood count, high-sensitivity C-reactive protein, serum biochemistry, identification of other respiratory pathogens (such as influenza A virus \[H1N1, H3N2, H7N9\], influenza B virus, respiratory syncytial virus, and adenovirus), and computed tomography of the thorax were applied to all high-risk cases. Following the isolation precautions, outpatients were sent to the fever clinic, which was located at the entrance of the hospital and was separated from the main entrance, while inpatients were sent to a separate room in the isolation ward. Contact and droplet precautions, including N95 respirator, gloves, waterproof disposable gowns, and eye protection, were applied to HCP and patients, when appropriate.

During January 23, 2020--February 10, 2020, a total of 129 patients of end-stage kidney disease (ESKD), ranging in age from 32 to 90 years, received HD sessions at the DU of the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China (geographical location is 30°16′ North, 120°12′ East, and the city has a registered population of 9.806 million in 2018). Among these, 6 patients presented with mild to moderate signs of infection and were identified as suspected or high-risk cases.

The data were obtained from the blood purification center of the First Affiliated Hospital of Zhejiang Chinese Medical University. Informed consent was signed before HD sessions. All suspected cases were systematically reviewed for exposure history where the local epidemiological situation was adapted, clinical features (new-onset symptoms and signs, laboratory results, and thorax CT scans), demographics, cause of ESKD, comorbidity, dialysis vintage, residual kidney function, presence of potential risk factors (diabetes and immunosuppressive therapy), Barthel \[[@B10]\] index for activities of daily living, admission history, clinical courses, and patient outcomes. Virology laboratory procedures were performed in accordance with the WHO protocol \[[@B11]\] in the laboratory unit of the First Affiliated Hospital of Zhejiang Chinese Medical University, and nasal or pharyngeal swab specimens were collected for high-throughput sequencing or real-time RT-PCR assay in all suspected or high-risk cases. A laboratory-confirmed case with COVID-19 was defined as a positive result to high-throughput sequencing or RT-PCR assay for nasopharyngeal and oropharyngeal swabs \[[@B12]\], according to the WHO interim guidance \[[@B8]\].

Results {#sec1_3}
=======

As of February 10, 2020, a total of 6 patients, ranging in age from 30 to 80 years, with a median vintage of 23.5 (interquartile range 3.75--42.50) months were identified as high-risk or suspected cases. Among these, 4 patients were female (4/6), 3 patients were diabetic (3/6), 4 patients had comorbid cardiovascular disease (4/6), 3 patients were anuretic (3/6), and one patient from the inpatient setting was on glucocorticoids for the treatment of idiopathic thrombocytopenic purpura (1/6). Lower level of serum albumin (≤38 g/L) and low BMI (≤18.5 kg/m^2^) were reported in 2 cases. The baseline demographic and clinical features are shown in Table [1](#T1){ref-type="table"}.

No patient had a travel history to Hubei Province, and 1 patient had an exposure history within the last 14 days to a local source of transmission. Respiratory symptoms and low oxygen saturation level were reported in 2 cases. Of the 5 cases with symptoms of fever, 2 were spotted at triage and 3 were detected during HD sessions. Detailed information on 6 suspected/high-risk cases is shown in Table [2](#T2){ref-type="table"}.

After the screening procedure, evidence of infection such as abnormal total blood cell count, elevated level of high-sensitivity C-reactive protein or procalcitonin, and radiographic findings related to pneumonia was found in 3 cases. Critical level of potassium (6.9 mmol/L) was reported in 1 case and partial pressure of oxygen dropping was found in 2 cases. After evaluation, 2 patients were transferred to an isolation/separate room in the ICU for bedside continuous renal replacement therapy (CRRT), and 1 patient was admitted to the isolation ward due to exposure history and respiratory symptoms.

Nasopharyngeal swab specimens were collected for virology tests, and two consecutive negative results (at least 24 h apart) were reported in all cases. Two cases with deteriorating condition requiring hospitalization were transferred to separate rooms in the nephrology ward for further treatment. After 2 days of monitoring, the remaining 4 patients were afebrile and no deterioration or new-onset symptoms were reported.

All 6 patients except for 1 patient without direct evidence of infection or epidemiological risk were scheduled in an isolated area on separate machines for their next HD sessions.

Discussion/Conclusion {#sec1_4}
=====================

With an estimated basic reproductive number varing in range from 2.7 to 4.2 \[[@B13]\], COVID-19 continues to spread. Due to the complexity of dialysis patients\' clinical picture, early implementation of IPC protocols in the DU is of paramount importance. In this study, we have reported a practical workflow for IPC and care delivery in a dialysis setting. Given different DU layout and design standards, it is impossible to unify routes in all dialysis settings. However, planning ahead for a worst-case scenario is advisable, such as necessary structural alteration, room partitioning for contingency use, contact surveillance, appropriate patient allocation strategies, intensified equipment cleaning and disinfection policies, and response measures in the event of detection of a suspected or confirmed case. It was reported that over 90% of the confirmed MERS-CoV cases in a DU were acquired by person-to-person transmission. During Ebola outbreak, Fresenius Medical Care (FMC) activated multidisciplinary collaboration \[[@B14]\]; measures including daily situation assessment through teleconference, providing staff-assisted HD limiting the exposed patients at home, evaluating exposure risk among HCP, preserving space for isolation, and applying contact precautions when needed substantially improved the capacity and preparedness for IPC and care delivery in dialysis settings during the epidemic.

Epidemiological studies showed that older age, diabetes, hypertension, and cardiovascular disease were risk factors among COVID-19 patients, indicating worse outcomes \[[@B15]\]. In this study, we have described cases with high risk or suspected infection of SARS-CoV-2. More than half of the identified cases were females, aged over 60 years, and had comorbid cardiovascular disease. Furthermore, half of the patients involved were diabetic and anuretic. Presence of immunocompromised status, hypoalbuminemia, and underweight were also noticeable in these cases.

Another particularly important lesson we learned from previous virus outbreaks is early identification of high-risk and suspected cases. As it was discussed during SARS outbreaks, dialysis patients tend to have atypical presentations, which is difficult to distinguish from uremic symptoms. Fever should set a high alert at the point of entry; however, only one-third of the febrile cases were detected at triage in our study. Close monitoring for temperature and oxygen saturation during HD sessions may be reasonable. On the other hand, more attention should be paid to differential diagnosis and timely evaluation. Although case confirmation mostly depends on virological testing, CT features of viral pneumonia may be strongly suspicious for COVID-19 despite negative RT-PCR results \[[@B16]\]. In our study, laboratory testing for complete blood count, hs-CRP, serum biochemistry, identification of other respiratory pathogens, and computed tomography of the thorax were included during the screening phase to help validate differential diagnosis. So far no confirmed COVID-19 cases were reported in our DU, but certain cases showed rapid deterioration due to other critically severe conditions. Since it is no longer a safe option to admit such patients in the nephrology ward for in-center dialysis, portable dialysis machines or CRRT machines are in great need to ensure dialysis care provision. Finally, after patients have been temporarily ruled out of CO­-VID-19, appropriate allocation and isolation strategies should be taken into account when rescheduling for the next HD sessions.

Based on the successful implementation of the renal replacement therapy, the last decade has witnessed a great advance in blood purification techniques. As the frontline of multiple organ support, extracorporeal organ support \[[@B17]\], including VV-ECMO, ECCO2R, VA-ECMO, intermittent and continuous HD, hemofiltration, hemodiafiltration, hemoperfusion, plasmapheresis, and sorbent therapies, has served its role in life support and provided an opportunity to improve patient outcomes in critical care settings \[[@B18], [@B19], [@B20]\]. It was reported that 5% of the confirmed cases was in need of intensive care during the COVID-19 outbreak \[[@B21]\]. Renal impairment was found in 63% of the COVID-19 cases in one ongoing case study \[[@B22]\], which may contribute to multiple organ failure and death \[[@B23]\]. As the situation of the current pandemic evolves, extracorporeal organ support readiness has become a crucial part of care delivery \[[@B24]\]. The golden hour of the rescue window in treatment of endotoxic shock was discussed before in the literature \[[@B25]\]. Despite the uncertainty of ideal timing, acute assessment in high-risk patients is fundamental; thus, rapid screening and turnaround testing for patients in need of acute dialysis are prioritized in our setting. In the context of COVID-19, awareness has been raised that ECMO itself may trigger the escalation of cytokine storm, and the combination of CRRT and hemoperfusion may be the solution to reduce cytokine insult \[[@B21]\]. Given the potential increase in renal replacement therapy utilization and anticipated ethical dilemmas, a paradigm shift is inevitable; organized and practical IPC measures in both dialysis and intensive care settings will go a long way in the current pandemic.

It is our unshakable duty to ensure dialysis care delivery in this emergency period. To our knowledge, clinical studies regarding IPC measures and clinical management of COVID-19 tailored to meet the needs in dialysis settings are scarce. Our study may serve the purpose of providing practical workflow for patient-centered management, and potential clinical feature identification of high-risk cases during the ongoing pandemic.
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![Workflow for patient-centered management in a dialysis setting during COVID-19 outbreak. \*Epidemiological investigation includes travel history, contact history, and other exposure history where the local epidemiological situation was adapted, as described in the WHO interim guidance \[[@B8]\]. \*\*Screening includes clinical assessment, laboratory testing for complete blood count, high-sensitivity C-reactive protein, serum biochemistry, identification of other respiratory pathogens (such as influenza A virus \[H1N1, H3N2, H7N9\], influenza B virus, respiratory syncytial virus, and adenovirus), and computed tomography of the thorax. HD, hemodialysis; HCP, healthcare personnel; COVID-19, coronavirus disease 2019; CRRT, continuous renal replacement therapy.](bpu-0001-g01){#F1}

![Workflow for the management of non-dialysis-dependent patients who have indications for acute dialysis when COVID-19 is suspected. \*Referring to immediate or delayed dialysis \[[@B26]\]; the latter means to start dialysis in response to severe metabolic acidosis, severe hyperkalemia, pulmonary edema, 72 h of oliguria, or a blood urea concentration of \>37 mmol/L. RRT, renal replacement therapy; ICU, intensive care unit; COVID-19, coronavirus disease 2019.](bpu-0001-g02){#F2}

###### 

Baseline demographic and clinical features for patients with suspected/high-risk of COVID-19

  Variable                           Value (*n* = 6) median (IQR) or count/no. of patients, %
  ---------------------------------- ----------------------------------------------------------
  Age, years                         65 (59--72)
  Age \>60 years                     4/6 (66.67%)
  Female gender                      4/6 (66.67%)
  HD vintage, months                 23.50 (3.75--42.50)
  Primary cause of ESKD              
   Glomerulonephritis                2/6 (33.33%)
   Diabetic kidney disease           2/6 (33.33%)
   Unknown                           2/6 (33.33%)
   Diabetes                          3/6 (50%)
   Cardiovascular disease            4/6 (66.67%)
   Hypertension                      6/6 (100%)
   Cancer                            1/6 (16.67%)
   Under immunosuppressive therapy   1/6 (16.67%)
   BMI, kg/m^2^                      19.43 (17.68--20.58)
   Urine output, mL/24 h             150 (0--1200)
   Hemoglobin, g/L                   105 (94--110)
   Serum albumin, g/L                39.5 (38.0--41.0)
   Phosphorus, mmol/L                1.86 (1.56--2.14)
   From inpatient settings           1/6 (16.7%)
   Barthel index (0--100) \< 100     1/6 (16.67%)
   Three HD sessions per week        6/6 (100%)

COVID-19, coronavirus disease 2019; IQR, interquartile range; HD, hemodialysis; ESKD, end-stage kidney disease.

###### 

Detailed information on 6 suspected/high-risk cases of COVID-19

  Case detail                                                       Value (median \[IQR\]) or count/patients, *n* (%)   Extra information
  ----------------------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Epidemiological risk                                              1/6 (16.67)                                         Patient has travel history within the last 14 days to a local endemic city
                                                                                                                        
  Temperature ≥37.5°C                                               5/6 (83.33)                                         Median (min-max) range of temperature: 37.7 (37.1--39.2) °C
                                                                                                                        
  Febrile detected at triage                                        2/6 (33.33)                                         
                                                                                                                        
  Respiratory symptoms                                              3/6 (50)                                            Mainly cough (3/6), sputum (1/6), shortness of breath (2/6)
                                                                                                                        
  Oxygen saturation \<93% on room air                               2/6 (33.33)                                         
                                                                                                                        
  Mean arterial pressure, mm Hg                                     115 (105--128)                                      
                                                                                                                        
  White blood cell count, ×10^9^/L                                  5.7 (5.0--6.5)                                      
                                                                                                                        
  Neutrophil percentage, %                                          72.45 (63.40--80.15)                                
                                                                                                                        
  Lymphocyte percentage, %                                          20.8 (11.0--21.5)                                   
                                                                                                                        
  Elevated level of hs-CRP and procalcitonin                        2/6 (33.33%)                                        
                                                                                                                        
  Abnormal ABGs                                                     2/6 (33.33%)                                        Arterial oxygen pressure dropping (PaO~2~ 63.6--71.7 mm Hg)
                                                                                                                        
  Hyperkalemia                                                      1/6 (16.67)                                         Critical level (*K* = 6.5 mmol/L)
                                                                                                                        
  Radiographic findings in chest CT scan                            4/6 (66.67%)                                        Patient 1: coarse patchy shadowing and peribronchial nodules in the upper lobe of the left lung
                                                                                                                        Patient 2: solid nodules and focal fibrosis in the lower lobe of the left lung
                                                                                                                        Patient 3: peripheral increased opacity with scattered fibrous stripes in the lower lobe of the right lung
                                                                                                                        Patient 4: focal consolidation with peripheral increased opacity in the lower lobe of the left lung, bilateral pleural effusion with lower lobe atelectasis
                                                                                                                        
  Admission to isolation room in ICU                                2/6 (33.33%)                                        Bedside CRRT
                                                                                                                        
  Admission to isolation ward                                       1/6 (16.67%)                                        
                                                                                                                        
  Positive result to SARS-CoV-2 virology testing                    0/6 (0%)                                            Virology procedure was repeated twice every 24 h
                                                                                                                        
  Positive result to other respiratory pathogens virology testing   0/6 (0%)                                            
                                                                                                                        
  Need hospitalization                                              2/6 (33.33%)                                        
                                                                                                                        
  Afebrile after 2 days of monitoring                               4/6 (66.67%)                                        
                                                                                                                        
  Rescheduled in an isolated area for the next HD sessions          5/6 (83.33%)                                        

COVID-19, coronavirus disease 2019; IQR, interquartile range; hs-CRP, high-sensitivity C-reactive protein; ABGs, arterial blood gas test; ICU, intensive care unit; CRRT, continuous renal replacement therapy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; HD, hemodialysis.
